Kai Yeung, PharmD, PhD, is a pharmacist and pharmaceutical economist with expertise in patient medication-use behaviors, insurance design, and outcomes research. His objective is to develop and evaluate incentives to encourage high-value use of health care services. Dr. Yeung has conducted research evaluating policies focused on specialty drug access, value-based insurance design, the consequences of insurance switching, and financial incentives. He combines applied econometric and cost-effectiveness analysis tools with a clinical understanding of prescription drugs and health insurance design to gain new insights in these areas.
Dr. Yeung has a line of research on designing and evaluating policies that align patient prescription drug out-of-pocket costs with estimated value using cost-effectiveness analysis. He has used econometric methods to quantify the impact of a value-based formulary on patient medication-utilization behavior, health outcomes and health care expenditures from patient and health care payer perspectives. For this work, Dr. Yeung successfully competed for two research grants: a multidisciplinary research training grant from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) and a health services research dissertation grant from the Agency for Healthcare Research and Quality (AHRQ). Different parts of this project were recognized by the International Society for Pharmacoeconomics and Outcomes Research 2014 and 2015 annual meetings as the best student podium presentation award, and the Vancouver Health Economics Methodology 2016 meeting as the best student paper award. Dr. Yeung continues to innovate in the generation and evaluation of this type of benefit design.
Dr. Yeung received his PhD in pharmaceutical economics from the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington and his PharmD from the University of Southern California. During his PharmD training, Dr. Yeung cultivated a broad perspective on the expanded use of evidence and analytics in decision-making, giving him experience in working with a diverse group of health care stakeholders, including:
Pharmacy benefit design, applied econometrics, healthcare costs, value-based insurance design, cost-effectiveness analysis, behavioral economics, alternative payment models, health policy evaluation
Pharmacoepidemiology of opioid use, identification of early onset Alzheimer’s disease
Design and evaluation of incentives for medication adherence
Patient and physician shared savings models to incentivize healthy behavior
Prevention and treatment
Yeung K, Suh K, Basu A, Garrison LP, Bansal A, Carlson JJ. Paying for cures: how can we afford it? managed care pharmacy stakeholder perceptions of policy options to address affordability of prescription drugs. J Manag Care Spec Pharm. 2017 Oct;23(10):1084-1090. doi: 10.18553/jmcp.2017.23.10.1084. PubMed
Yeung K, Li M, Carlson JJ. Using performance-based risk-sharing arrangements to address uncertainty in indication-based pricing. J Manag Care Spec Pharm. 2017 Oct;23(10):1010-1015. doi: 10.18553/jmcp.2017.23.10.1010. PubMed
Yeung K, Basu A, Marcum Z, Watkins JB, Sullivan SD. Impact of a value-based formulary in three chronic disease cohorts. Am J Manag Care. 2017 Mar;23(3 Suppl):S46-S53. doi: 87035. PubMed
Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD. Impact of a value-based formulary on medication utilization, health services utilization, and expenditures. Med Care. 2016 Aug 30. [Epub ahead of print]. PubMed
Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB. Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm. 2015 Apr;21(4):269-75. PubMed
A study among KP members with sleep problems and osteoarthritis shows promise for overcoming obstacles to treatment.
Now more than ever we can benefit from studies embedded in health-care systems to answer common clinical questions.
Kaiser Permanente Washington shows price may not be a barrier to primary care implementation, Dr. Kai Yeung reports.
Physicians Weekly, April 1, 2021